Navana Pharmaceuticals PLC announcements
122 Dhaka Stock Exchange announcements for Navana Pharmaceuticals PLC (NAVANAPHAR) since 2022: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2024 (40).
- Credit Rating Result
National Credit Ratings Limited has assigned the Surveillance entity rating of the Company as "AA" in the long term and "ST-2" in the short term along with Stable outlook based on audited financial statements as on June 30, 2024 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Emphasis of Matter
The auditor of the company has given an "Emphasis of Matter" paragraph in the audited financial statement of the company for the year ended June 30, 2024. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2024/November/NavanaPhar_2024.pdf
- Resumption after Record Date
Trading of the shares of the company will resume on 20.11.2024.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 19.11.2024.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 1.25 for July-September 2024 as against Tk. 1.11 for July-September 2023; NOCFPS was Tk. 2.00 for July-September 2024 as against Tk. 1.19 for July-September 2023. NAV per share was Tk. 43.51 as on September 30, 2024 and Tk. 42.46 as on June 30, 2024. (cont.) (Cont. news of NAVANAPHAR): Reasons for deviation: EPS has increased due to increase in sales revenue and efficient usages of material resulted in increased gross profit for the reporting period. NOCFPS has increased due to cash received from the customers was higher than the cash payment to the vendors in the reporting period. (end)
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 17.11.2024 to 18.11.2024 and trading of the shares of the company will remain suspended on record date i.e., 19.11.2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2024 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.
- The company has requested the members to update their Bank Account Number, Taxpayer\'s Identification Numbers (e-TIN), A
The company has requested the members to update their Bank Account Number, Taxpayer\'s Identification Numbers (e-TIN), Address, E-mail address and cell no. before the record date to their respective depository participant. The company has also requested the concerned brokerage houses and merchant bankers to provide with a statement with the details (shareholders name, BOID number, e-TIN number, gross dividend receivable, applicable tax rate, and net dividend receivable) (cont.)
- Update of Information
(Continuation news of NAVANAPHAR): of their margin loan holders who hold shares of the company as on the Record Date, along with the name of the contact person in this connection. The brokerage houses and merchant bankers are also requested to provide us with their Bank Account Name, Number, Routing number etc. on or before 10 December 2024. (end)
The first part of this announcement is missing from the archive. - The Board of Directors has recommended 14\% Cash Dividend only for General Shareholders (Sponsor shareholders and Direct
The Board of Directors has recommended 14\% Cash Dividend only for General Shareholders (Sponsor shareholders and Directors and few shareholders who hold significant share of the company will not receive any dividend). Total Paid-up share 107,416,217, Director and Sponsor are hold 38,857,014 nos. shares and 34,665,622 nos. share are hold other shareholder who are willingly forgo their dividend along with Director and Sponsor for the betterment of the company. (cont.)
- Dividend Declaration
(Cont. news of NAVANAPHAR): Whereas BDT 47,451,014.00 payable to the General Shareholders as 14% Cash Dividend. AGM: 31.12.2024, Time: 3:30 PM, Venue: Registered office: 1071, 1073, North Rupshi, Tarabo Municipality, Rupganj, Narayanganj. Record Date: 19.11.2024. The Company has also reported EPS of Tk. 3.77, NAV per share of Tk. 42.46 and NOCFPS of Tk. 6.58 for the year ended June 30, 2024 as against Tk. 3.59, Tk. 40.71 and Tk. 1.80 respectively for the year ended June 30, 2023. (end)
The first part of this announcement is missing from the archive. - Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.10.2024) following its corporate declaration.
- Change of registered office address of the company
The company has informed that they have decided to change the registered office of the company to 1071, 1073, North Rupshi, Tarabo Municipality, Rupganj, Narayanganj from 125/A, Motijheel C/A, Dhaka with immediate effect subject to obtaining approval from relevant regulatory authorities.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2024 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
- Appointment of Chairman
The company has informed that the Board of Directors has decided to appoint Professor Dr. Sarder A. Nayeem (Nominated Director of Stratus Holdings Limited) as Chairman of the company with effect from September 18, 2024.
- Emphasis of Matter
The auditor of the company has given the "Emphasis of Matter" paragraph in the Report on the Audit of IPO (Initial Public Offering) Proceeds Utilization Statement, for the quarter ended on 30 June 2024. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2024/july/Navana%20Pharmaceuticals%20PLC.-30-06-24.pdf
- Refer to their earlier news disseminated by DSE on 10.03.2024, the company has further informed that that the shareholde
Refer to their earlier news disseminated by DSE on 10.03.2024, the company has further informed that that the shareholders of the company in its 7th Extraordinary General Meeting held on May 07, 2024 has approved to change the Use of Proceeds of IPO fund regarding Modernization and Expansion of SVPO Facility of BDT 13.12 crore (17.49\%) of the total IPO proceeds of BDT 75 crore and replace it construction of new Generic Production Unit, (cont.)
- Regarding Board approval for change in the use of IPO proceeds
(Continuation news of NAVANAPHAR): also has approved to extend the time of full utilization of Initial Public Offering (IPO) proceeds within 36 months after receiving IPO proceeds to accommodate the proposed changes in Use of IPO Proceeds. (end)
The first part of this announcement is missing from the archive. - (Q3 Un-audited): EPS was Tk. 1.00 for Jan-March 2024 as against Tk. 1.09 for Jan-March 2023; EPS was Tk. 3.09 for July 2
(Q3 Un-audited): EPS was Tk. 1.00 for Jan-March 2024 as against Tk. 1.09 for Jan-March 2023; EPS was Tk. 3.09 for July 2023-March 2024 as against Tk. 2.57 for July 2022-March 2023. NOCFPS was Tk. 1.59 for July 2023-March 2024 as against Tk. 2.85 for July 2022-March 2023. NAV per share was Tk. 42.11 as on March 31, 2024 and Tk. 40.71 as on June 30, 2023. (cont.)
- Q3 Financials
(Continuation news of NAVANAPHAR): Reasons for significant deviation in EPS and NOCFPS: Increment of EPS up to the reporting period because of growth of sales revenue and Gross Profit as well as optimum cost management policy. Due to the quick payment strategy to suppliers and others net cash flow from operating activities has decreased in the reporting period, resulting in decreased NOCFPS. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2024 at 03:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2024.
- Emphasis of Matter
The auditor of the company has given the "Emphasis of Matter" paragraph in the Auditor's Report of the company for the quarter ended March 31, 2024. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2024/mar/NAVANAPHAR2024.pdf
- Refer to their earlier news disseminated on 10.03.2024 regarding EGM to change in the use of proceeds of IPO, the compan
Refer to their earlier news disseminated on 10.03.2024 regarding EGM to change in the use of proceeds of IPO, the company has further informed that due to some unavoidable circumstances the Board of Directors of the company has re-fixed its 7th EGM in May 07, 2024 instead of May 02, 2024 and other things will remain the same in this regard. (cont.)
- Re-fixation of EGM date
(Cont. news of NAVANAPHAR): Time of 7th EGM: 12:30 PM. Venue of the Hybrid EGM: LAVITA Hall, Lakeshore Hotels (Gulshan), at House-46, Road-41, Gulshan, Dhaka-1212. Link of EGM: https://navanaphar.digitalegmbd.net. (end)
The first part of this announcement is missing from the archive. - Appointment of new Company Secretary
The Company has informed that the Board of Directors of the company in its meeting held on April 02, 2024 has decided to accept the resignation letter of Company Secretary Mr. Joynul Abedin ACS from the said position and appointed Mr. Lorens Shamol Mollick FCS as Company Secretary of the Company.
- Resumption after Record date
Trading of the shares of the company will resume on 03.04.2024.
- Suspension for Record date
Trading of the shares of the company will remain suspended on record date i.e., 02.04.2024.
- BSEC consent to issue Navana Pharmaceuticals Partial Convertible Bond
Refer to their earlier news disseminated by DSE on 12.06.2023, the Company has further informed that the Bangladesh Securities and Exchange Commission (BSEC) has given its kind consent to issue Navana Pharmaceuticals Partial Convertible Bond amounting BDT 150 crore (Taka one Fifty Crore) at face value per unit BDT 100,000 (One lac) only vide its Consent Letter dated March 27, 2024, to refinance the existing bank loan of the company. The full payment of the Bond is backed by Bank Guarantee.
- Spot for EGM
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with from 31.03.2024 to 01.04.2024 and trading of the shares will remain suspended on record date i.e., 02.04.2024 for EGM.
- Decision on construction of New Generic Production unit: The Board of Directors of the company has decided to construct
Decision on construction of New Generic Production unit: The Board of Directors of the company has decided to construct a 5-storied fully GMP Compliant New Generic Production unit with an initial investment of around BDT 145.27 crore. Total footprint area will be 20,000 sq.ft. approximately where 1 (one) Production floor is to be fit out. This will enhance existing production capacity by around 1,000 Million units yearly. (cont.1)
- (Cont. news of NAVANAPHAR): Decision on change in the Use of Proceeds of IPO Partially & Extend the time of full utiliza
(Cont. news of NAVANAPHAR): Decision on change in the Use of Proceeds of IPO Partially & Extend the time of full utilization of Initial Public Offering (IPO) Proceeds: i. The Board of Directors of the company has decided to change the Use of Proceeds of IPO fund, whereas an amount of BDT 13.12 crore was earmarked for Modernization and Expansion of SVPO Facility. (cont.2)
The first part of this announcement is missing from the archive. - (Cont. news of NAVANAPHAR): Now the Board has decided to use the fund in the construction of new Generic Production Unit
(Cont. news of NAVANAPHAR): Now the Board has decided to use the fund in the construction of new Generic Production Unit. The company has already completed 71.31\% of total IPO proceeds of BDT 75 crore. ii. The details of the recommended revised use of proceed of IPO are as follows: 1) Existing approved IPO use of Proceeds: Modernization and Expansion of SVPO Facility; Amount (Tk.): 131,185,000.00. (cont.3)
The first part of this announcement is missing from the archive. - (Cont. news of NAVANAPHAR): 2) Revised (Recommended) IPO use of Proceeds: Construction of new Generic Production unit: a
(Cont. news of NAVANAPHAR): 2) Revised (Recommended) IPO use of Proceeds: Construction of new Generic Production unit: a) Amount (Tk.): 131,185,000.00 (To be used from IPO proceeds) and b) Amount (Tk.): 1,321,549,375.00 (To be financed from company\'s Internal & External Sources). Total 1,452,734,375.00 Taka. (cont.4)
The first part of this announcement is missing from the archive. - (Cont. news of NAVANAPHAR): iii. The Board also has decided to extend the time of full utilization of Initial Public Off
(Cont. news of NAVANAPHAR): iii. The Board also has decided to extend the time of full utilization of Initial Public Offering (IPO) proceeds within 36 months after receiving IPO proceeds to accommodate the proposed changes in Use of IPO Proceeds. The above are subject to obtaining approval from the shareholders of the Company in its upcoming 7th Extra Ordinary General Meeting (EGM). (cont.5)
The first part of this announcement is missing from the archive. - EGM to Change in the use of proceeds of IPO
(Cont. news of NAVANAPHAR): iv. Information relating upcoming Extra Ordinary General Meeting:- Date of Extra Ordinary General Meeting (EGM): May 02, 2024. Record Date: Tuesday, April 02, 2024. Venue, link & Time of hybrid EGM Will be notified later on due course. (end)
The first part of this announcement is missing from the archive. - Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2023 to the respective shareholders.
- (Q2 Un-audited): EPS was Tk. 0.98 for October-December, 2023 as against Tk. 0.77 for October-December, 2022; EPS was Tk.
(Q2 Un-audited): EPS was Tk. 0.98 for October-December, 2023 as against Tk. 0.77 for October-December, 2022; EPS was Tk. 2.09 for July-December, 2023 as against Tk. 1.57 for July-December, 2022. NOCFPS was Tk. 0.87 for July-December, 2023 as against Tk. 0.87 for July-December, 2022. NAV per share was Tk. 41.33 as on December 31, 2023 and Tk. 40.71 as on June 30, 2023. (cont.)
- Q2 Financials
(Continuation news of NAVANAPHAR): Reasons for deviation in EPS: Increase in Sales revenue and efficient usages of material resulted in increased gross profit as well as increment of EPS. (end)
The first part of this announcement is missing from the archive. - Name Change of the Company
Dhaka Stock Exchange PLC. (DSE) has approved the proposed name change of the Company. Accordingly, the name of the Company will be 'Navana Pharmaceuticals PLC' instead of 'Navana Pharmaceuticals Limited' with effect from January 28, 2024. Other things (except name) will remain unchanged.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2024 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.